SUMMARY The influence of nifedipine on left ventricular ejection fraction, infarct size, and infarct expansion was studied in a prospective, double blind, randomised, placebo controlled trial in 132 patients with low risk acute myocardial infarction of < 12 hours duration, defined by an initial left ventricular ejection fraction >35% and clinical Killip class of <II. Sixty four patients were assigned to nifedipine 120 mg/day and 68 to placebo. Treatment was started on average (SEM) 8-0 (0 2) hours after onset of pain and continued for six weeks. Gated blood pool scans, thallium scans, and cross sectional echocardiograms were performed before treatment and at 10 days. There were no significant differences between the two groups in age, sex, cardiac risk factors, or use of other medications. Mean (SEM) global left ventricular ejection fraction was not different before treatment (nifedipine group 53 (2%), placebo group 55 (2%) and did not differ at 10 days (nifedipine group 54 (2%), placebo group 52(2%). There were also no differences in regional wall motion or regional ejection fractions. Thallium defects quantified by computer analysis were similar in both groups before treatment (nifedipine 7-8 (0-7), placebo 7 9 (0-7)) and at 10 days (nifedipine 5-3 (0-7) placebo 5-3 (0-7)). In the subgroup of patients with transmural infarction who had good quality echocardiograms and serial studies (n = 30), there was no difference in mean (SEM) baseline infarct segment lengths between the two groups (nifedipine 70(4) mm, placebo 65 (4) mm); however, the nifedipine group demonstrated no significant change in infarct segment length between the initial and 10 day studies (+ 0-6 (3) mm) while there was a significant increase in the infarct segment length in the placebo group (+ 7-8 (4) mm). The infarct segment length increased by > 1 cm in seven (47%) placebo patients but in only one (7%) nifedipine patient. The nifedipine group had a significant initial 10% decrease in mean arterial pressure whereas there was no change in the placebo group; this blood pressure difference persisted for 10 days.
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angina,'* and there are theoretical reasons to suggest that it may also be beneficial in the treatment of acute myocardial infarction. These include a reduction of afterload mediated by peripheral vasodilatation, an increase in coronary flow via coronary vasodilator and antispasm effects, and the possibility of a direct protective effect on the myocardium. Animal studies have shown a reduction ofinfarct size with nifedipine given before and after coronary occlusion."' In addition, nifedipine may limit infarct expansion because left ventricular wall tension is an important determinant of expansion when the infarction is transmural. '1'4 Several controlled studies have examined the effect of the early administration of nifedipine in patients with acute myocardial infarction and have demonstrated no significant reduction in myocardial infarction size measured by creatine kinase release.""17 One of these studies suggested that there may be an increased early mortality associated with nifedipine treatment15; however, the TRENT study which randomised 4491 patients showed no significant effect of lower dose nifedipine treatment (10 mg four times daily) on After the patient had given informed consent to one of the study investigators, baseline thallium and gated blood pool scans were obtained in the coronary care unit with a portable gammacamera. These studies were performed by a 24 hour on-call team of experienced research nuclear cardiology technicians and were completed within 1-5-2 hours. After completion of the initial scans, the patients received, in a randomised double blind fashion, one capsule of the study drug, which was either nifedipine 10 mg or a placebo capsule of identical appearance. Blood pressure was monitored every 10 minutes for one hour by a research nurse, and ifthe mean arterial pressure fell by < 10% and the systolic blood pressure was > 100 mm Hg a second study drug capsule was given. The pressure was similarly monitored for the next hour, and if the mean arterial pressure fell by < 10% and the systolic blood pressure remained > 100 mm Hg a third capsule was administered with an additional hour of monitoring. Thus a maximum maintenance study drug dose of 10-30 mg was established in each patient and this was then given every six hours for six weeks unless hypotension or any other side effect was noted.
Repeat gated blood pool scanning was performed immediately after the determination of the maintenance study drug dose and again at 10 days. Cross sectional echocardiograms were obtained within 24 hours of admission and again at 10 days in those patients who had technically interpretable initial echocardiographic studies. Twelve lead electrocardiograms were obtained daily while the patients were in the coronary care unit, and creatine kinase isoenzyme concentrations were measured every four hours for the first two days.
Routine coronary care unit management included oxygen by nasal cannula, intravenous lignocaine infusion for 24-48 hours pg/kg/min), and full heparinisation (3000 unit bolus followed by 800- were separated into infarct and non-infarct zones by electrocardiographic correlation and by the assessment of regional wall motion abnormalities. A regional ejection fraction was then calculated for each zone from the mean of the adjacent 22. 5 pre-shaped sectors overlying the left ventricle, excluding the upper medial quadrant. Once they had been defined on the initial study, the same sectors were used to calculate regional ejection fractions for infarct and non-infarct zones on serial studies. The gated blood pool and thallium scans were interpreted blindly without knowledge of the study assignment.
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CROSS SECTIONAL ECHOCARDIOGRAPHY
Serial cross sectional echocardiography was performed on days 1 and 10. Particular attention was given to obtaining a good cross sectional view at the level of the papillary muscles. The serial studies were quantitatively analysed blindly by a trained technician and then reviewed blindly by an investigator (JLW). Endocardial anterior and posterior segment lengths from cross sectional end diastolic frames at the level of the papillary muscles were measured in triplicate with a computer-aided contouring system and averaged by previously published methods. ' 30 minutes with new electrocar-413 diographic changes and re-elevation of creatine kinase concentrations to greater than twice normal, recurrent ischaemia, and the need for coronary artery bypass surgery to control ischaemic symptoms were also examined, although the study population was not large enough to detect even large mortality differences. The calculated sample size of this study was sufficient to detect an approximate 50%o difference in combined clinical outcomes (death, recurrent infarction, bypass surgery for recurrent angina symptoms) with a power of 0 7.
DATA ANALYSIS
Continuous variables were analysed by paired and non-paired t tests as appropriate. Categorical data were examined by contingency-table analysis by the x2 test. The proportion of patients in each study arm who experienced individual and combined clinical outcomes and the time-dependence of these outcomes were analysed by Kaplan-Meier actuarial curves, which were compared by a log-rank test with a two-tailed significance level.20 Repeated measures analysis of variance was used to compare the blood pressures in the two groups over time. The gated blood pool scan, thallium scan, and echocardiographic data were interpreted blindly without knowledge of study drug assignment or clinical course. Data are presented as mean (SE). The analyses include all patients originally assigned to each treatment arm, according to the intention to treat principle.
Results
A total of 132 patients were randomised: 64 were assigned to nifedipine and 68 to placebo. Table 1 shows the clinical characteristics of the study population. The patients were 33 to 75 years old and 67% were men. The mean time from the onset of chest pain to the start of treatment with the study drug was 8-0 (0-2) hours for all patients. There were no significant baseline differences in the distribution of cardiovascular risk factors including previous myocardial infarction, treatment with other antiischaemic agents, initial Killip class, location of myocardial infarction, presence ofnon-transmural or transmural infarctions, size of the initial thallium defect, or initial left ventricular ejection fraction by gated blood pool scan performed before treatment.
HAEMODYNAMIC RESPONSE TO STUDY DRUG
The figure shows the mean arterial blood pressure response to the first maintenance study drug dose after completion of dose titration. The mean dose of nifedipine in the group randomised to nifedipine was 105 mg/day: 39 patients received 120 mg/day, 19 Table 2 shows the clinical outcomes over the six week study period. Eight patients (four nifedipine, four placebo) were withdrawn from the study because of side effects. The side effects in the nifedipine group were hypotension in three and dizziness in one patient. One placebo patient was withdrawn because of hypotension and three because of dizziness and other non-specific complaints attributed to the study drug. Two other patients assigned to nifedipine and four assigned to placebo withdrew themselves prematurely from the study. The analyses of the clinical outcomes include all patients who were originally assigned to each treatment arm. Six nifedipine and seven placebo patients demonstrated no subsequent enzymatic evidence of myocardial infarction but were included in the analyses. There was no difference in the peak creatine kinase concentrations between the nifedipine (1383 (150) IU) and the placebo (1626 (152)) groups. Four patients in each treatment arm died within six weeks (6% overall mortality), and six nifedipine and seven placebo patients experienced recurrent myocardial infarction. Five nifedipine and two placebo patients underwent coronary artery bypass surgery within six weeks for persistent post-infarction angina. Thus 23% of the nifedipine patients and 19% of the placebo patients experienced either death, reinfarction, or bypass surgery for symptoms at six weeks, and there was no significant group difference for the cumulative time dependent probability of experiencing any of these outcomes (Kaplan-Meier analysis).
In order to detect a statistically significant difference of this magnitude with an alpha level of 0-05 and a power of 0-8 over 1400 patients would be required in each arm of the study.
LEFT VENTRICULAR FUNCTION Table 3 shows the global and regional left ventricular function data. There is no significant difference in baseline global ejection fractions between the nifedipine (53 (2)%) and placebo (55 (2)%) groups. There are also no differences in the immediate post- Bypass surgery for symptoms 5 2 Side effects requiring withdrawal from study 4 4 Study withdrawals because of non-compliance 2 4 *There is no significant difference between the two groups for any of the variables listed.
group
Nifedipine in acute myocardial infarction treatment (nifedipine 54 (2)%, placebo 54 (2)%) or 10 day (nifedipine 54 (2)%, placebo 52 (2)%) studies.
The present sample size is sufficient to detect a 10% difference (that is between a 50% and a 55% ejection fraction) in the mean ejection fraction between the two study groups with an alpha level of 0-05 and power of 0-7. When analysed as paired data, neither group showed a statistically significant in ejection fraction between the initial and 10 day scans. Since patients with low initial ejection fractions tend to show improvement with time while those with high initial values tend to demonstrate a reduction as the high initial sympathetic tone decreases,21 the change in ejection fraction was also analysed separately in the subsets of nifedipine and placebo patients with an initial ejection fraction < 50% and in those with an initial ejection fraction of > 50%. No nifedipine effect was demonstrated as there was a similar improvement over the 10 day period in patients with a low initial ejection fraction, and a similar decline in global ejection fraction in the subset with a high initial ejection fraction. In the subgroup of patients who received early treatment (<6 hours from pain onset) there is also no significant difference in 10 day global ejection fraction between the nifedipine and placebo patients. Initial and day 10 cardiac output and ventricular volumes also were not significantly different in the nifedipine and placebo groups (table 3). The pretreatment 415 infarct zone regional ejection fractions were 33 (2)% in the nifedipine and 35 (2)% in the placebo groups (NS). The regional ejection fractons of the noninfarct zone were 61 (1-3)% in the nifedipine and 64 (1-5)% in the placebo groups (NS). At 10 days the ejection fractions of the infarct zones were significantly improved in both the nifedipine (+ 6 (2)%) and placebo groups (+7-5 (2)%) and there was no difference between the two groups. In contrast, the regional non-infarct zone ejection frctions were minimally reduced in both the nifedipine (-3 (17)%) and placebo groups (-4 (1-6)%, table 3). Thus the net change in global ejection fraction over the 10 day period is determined by opposite trendsan increase in the infarct zones and a decrease in the non-infarct zones.
THALLIUM SCINTIGRAM RESULTS
The initial and 10 day thallium perfiusion images were analysed quantitatively by mthods described elsewhere.'5 The initial preratment thallium scores in the nifedipine (7-8 (0.7) units) and placebo (7) (8) (9) (0-7) units) groups did not differ. The day 10 thallium score was lower in both groups and also did not differ significantly (nifedipine 5-3 (0-7), placebo (0-7)). Thus quantitative analysis of myo ial infarction size by serial (at the start ofthe trial and 10 days later) thallium scintigraphy showed no nifedipine effect. Anterior/inferoposterior MI 2/13 4/11 Age (years) (mean (SEM)) 55 (3) 59 (1) Time from onset of chest pain to 6-9 (0 5)
70 (4) 65 (4) (mean (SEM)) *(p < 0-05). There is no significant difference between the groups for any other characteristic listed. MI, myocardial infarction;
LVEF, left ventricular ejection fraction.
less, there was a significant increase in infarct segment length (+ 7-8 (4) mm, p < 0-05) in the placebo group between the studies on day 1 and on day 10, and none in the nifedipine group (+0-6 (3) mm, p = NS). The infarct segment length increased by > 1 cm in seven patients assigned to placebo but in only one assigned to nifedipine (p < 0-05). Both groups showed a similar increase in the non-infarct segment lengths (nifedipine 9 (4) mm, placebo 8 (4) mm, p = NS). As in the overall study population, the nifedipine group in this echocardiographic analysis showed a significant fall in systolic blood pressure 40 minutes after receiving the initial maintenance dose of the study drug (-8-1 (1) mm Hg, p = 0-04), while the placebo group did not. This difference between the groups persisted over 10 days (p < 0-05 by repeated measures analysis), and the 10 day mean arterial pressures were 81 (1) mm Hg in the nifedipine group and 87-3 (1) mm Hg in the placebo group (p = 0-02). The cardiac volumes measured by gated blood pool scans in this subgroup were not significantly different in the two treatment groups. The non-infarct segment lengths increased similarly in both groups and this may have masked differences caused by changes in infarct segments.
Discussion
The present study shows that nifedipine given to patients with acute myocardial infarction within 12 hours of the onset of pain has no detectable effect on global or regional left ventricular function or myocardial infarct size by thallium scintigraphy. The Gottlieb, Becker, Weiss, et al power of this individual study to detect a significant difference in mortality and reinfarction is quite low, but the present findings are consistent with other published reports of early nifedipine treatment in acute infarction."'7 The echocardiographic findings in a subset of patients with transmural infarction, however, suggest that early nifedipine treatment in a dose sufficient to lower mean arterial blood pressure by approximately 10% may decrease the occurrence and extent of infarct zone expansion. The clinical significance of this observation is unclear, however, and these data must be interpreted with caution as they apply to a relatively small and selected subset of the study population.
Theoretical considerations and studies in animal models suggesting that calcium antagonist treatment may limit infarct size have prompted considerable interest in the role of these agents in patients with an acute myocardial infarction."" These drugs reverse coronary vasoconstriction, which may accompany an infarction22 and may be the proximate cause of coronary artery occlusion in some patient subsets.2"
They may also improve myocardial oxygen supply and decrease oxygen demand by increasing collateral flow and decreasing afterload via their vasodilatory effects on the coronary and peripheral circulation. 24 Although treatment with calcium antagonists reduced infarct size in some animal studies,"' the effect was studied only when the agent was given before or within one hour of the onset of ischaemia. In addition, the effect may be dependent on a collateral network capable of delivering the agent to the ischaemic area itself since the benefit in dogs, which have well developed collaterals, is considerably greater than that in baboons,25 which do not.
There have been four other randomised controlled studies examining the effect of nifedipine in patients with threatened or actual acute infarction."5 '7 26 These have focused on the enzymatic determination of infarct size and on the clinical course. A Norwegian trial showed no significant difference in creatine kinase release in the nifedipine and placebo groups.'6 Another study also reported no significant difference in infarct size estimated by creatine kinase release, but reported a higher two week mortality in the nifedipine treatment group that was not present at six months."5 These trials were also too small to detect differences in major clinical outcomes such as mortality; however, the largest trial of nifedipine in suspected or confirmed acute infarction (the TRENT study) found that a daily dose of 40 mg of nifedipine had no significant effect on one month mortality in 4491 randomised patients. '7 The lack of a reduction in infarct size or of a significant difference in major clinical outcomes in all of these trials may be related to several factors.
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Although nifedipine is a potent coronary vasodilator, coronary vasoconstriction may have a relatively small role in most infarct patients. Even if spasm is an inportant initiating event, the superimposition of thrombus may prevent reperfusion with antispasm treatment alone.27 In addition, any direct protective effect is dependent on the extent of collateral supply to the infarcted region, which is usually limited in patients with initial transmural infarctions.'2 Finally, reperfusion studies have indicated that strategies designed to salvage myocardium must be started immediately after the onset of ischaemia.'" The mean time from the development of chest pain to treatment in these trials ranged from 46 to 8 hours, which is probably too long to achieve significant myocardial salvage.
These negative results with calcium antagonist treatment in non-selected acute infarction patients (most of whom had completed Q wave infarctions) contrast with other data supporting the efficacy of anti-ischaemic drugs for selected subsets of high risk patients in whom the potential for recurrent ischaemia after infarction is increased. The beneficial effect of calcium antagonist treatment in reducing early reinfarctions in patients with non-Q-wave infarctions,"2 the benefit of nifedipine for patients with post-infarction angina,8 33 and the reduction of cardiac mortality by ,B blockers, most notably in high risk subgroups,'346 collectively suggest that nonthrombolytic anti-ischaemic treatment is likely to be beneficial only in patients with high potential for recurrent ischaemia, such as non-Q-wave infarction patients.
The serial echocardiographic findings in the subset of patients with transmural infarction suggest that the effect of nifedipine in reducing afterload may limit the expansion of the infarct zone during the ten days after an infarction. Although early expansion of the infarct is associated with an early increase in morbidity and mortality and the late development of left ventricular aneurysms,'2"14 the number of patients in the present trial with infarct expansion is too small for a difference in clinical outcome to be detected even if one were present. In addition, our population included many patients with inferior infarctions, in whom the clinical significance of infarct expansion is uncertain. A recent controlled study showing that intravenous glyceryl trinitrate and early intra-aortic balloon counterpulsation in patients with extensive anterior infarctions and low ejection fraction reduce the expansion into the noninfarcted area also suggests that afterload reduction may favourably influence the remodelling of the ventricular cavity that occurs after infarction.'7 Other agents which reduce afterload have been reported to have a favourable effect on infarct expansion includmg glyceryl trinitrate in humans' and captopril in rats,39 suggesting that the afterload reduction itself may be the mechanism for this effect.
The time course of myocardial necrosis in human beings seems to be rapid, and interventions designed to limit infarct size should be started as early as possible.' The mean time between the onset of chest pain and treatment in this study was 8 (0-2) hours, primarily because the study design required baseline thallium and gated blood pool scans before the start of treatment in order to assess the effect of the agent on left ventricular function and the thallium scintigraphic definition of infarct size relative to the region at risk. The additional delay introduced by these baseline studies may have limited our ability to demonstrate a treatment benefit. Nevertheless, the analysis of the patient subset that received treatment within six hours, as well as previous studies"'7 in which nifedipine treatment was initiated 4-6 hours after the onset of pain, also showed no benefit of nifedipine. At the present time, the collective results of the randomised nifedipine trials demonstrate no significant clinical benefit of nifedipine given in low or high doses. 
